Blog - Page 4593 of 5516

FridayApr 11, 2008 9:41 am

CopyTele, Inc. (COPY.OB) Indian Government Approves License Agreement Between CopyTele and Videocon Industries Limited of India

CopyTele, Inc., a developer, producer, and marketer of thin, flat, low-voltage phosphor displays and multi-functional encryption products, announced that the Indian Government has approved the license agreement between CopyTele and Videocon Industries Limited, a 3.5 billion dollar U.S. flagship company of the Videocon Group, under which Videocon will manufacture and market products, including TVs, utilizing CopyTele’s display technology. The approval of the Indian Government was the sole condition to effectiveness of the license agreement. CopyTele will receive a license fee of $11 million from Videocon, which is payable in installments over a 27-month period, and a royalty based on display…

FridayApr 11, 2008 9:34 am

AQUAGOLD International, Inc. (AQUI.PK) Announces Consolidated Results in Primary Sales Contract for Total Revenue of $118 Million.

AQUAGOLD, a company that has developed a national network of retailers and points of sale in preparation for the highly anticipated launch of its line of premium spring water products in China, revealed details of its 8-year sales agreement. AQUAGOLD has proceeded with an initial consolidation of orders stemming from end users at the retail level. The consolidation results in a primary sales contract that shows slightly less than 17 million cases of product for a total revenue of $118 million dollars. The initial purchase orders are currently being finalized. AQUAGOLD’s President and CEO, Daniel Sauvé commented, “It is a…

FridayApr 11, 2008 9:31 am

Altair Nanotechnologies, Inc. (ALTI) Names Robert G. van Schoonenberg Director of Board, Expanding the Board to Seven Members

Altair Nanotechnologies, Inc., an innovator and supplier of advanced, novel, ceramic nanomaterials, announced it expanded its board to seven members by naming Robert G. van Schoonenberg as director. Mr. Schoonenberg also serves as Chair of the Audit Committee and as a member of the Compensation, Nominating and Governance Committee. Jon Bengtson, Altair Nanotechnologies Chairman commented, “Bob van Schoonenberg is a seasoned executive whose depth of experience in strategic planning, corporate governance and executive leadership greatly enhances the Altairnano Board. Bob has served in various legal and executive capacities for Fortune 500 companies for more than 30 years. In addition, his…

FridayApr 11, 2008 8:54 am

Don’t Leave “Success” Out of Succession

One in five family business participants has not addressed any estate conservation issues beyond writing a will. Business continuation is difficult enough under normal circumstances, but if it has to take place following the unexpected death of a key person or owner, the complications can increase exponentially. Company-owned life insurance is one way to help protect a business from financial problems caused by the unexpected death of a key employee, partner, or co-owner. If the covered individual dies, the proceeds from this type of insurance can help in several ways. Here are some examples. Fund a Buy-Sell Agreement A buy-sell…

FridayApr 11, 2008 8:52 am

A Tale of Two Investments

Investors often wonder whether growth stocks are preferable to value stocks, or vice versa. Although no one can forecast future performance, over the past 10 years, value stocks provided an 11% average annual return, and growth stocks provided a 5.44% average annual return. So what does this mean for the growth and value stocks in your portfolio? Is it time to ditch your growth stocks in favor of value stocks? Not necessarily. Investing fads come and go, but a diversified strategy involving growth, value, or a combination of the two can be a great addition to your investment portfolio. Room…

FridayApr 11, 2008 8:51 am

Retirement Reality Check

It's easy to tell yourself that you'll be okay in retirement, especially when it's still years away. But you get only one chance to save for retirement. If you arrive at retirement’s door without adequate resources, you may have limited options. One way to help avoid mistakes is to do a retirement reality check: review the assumptions that guide your decisions to ensure that they are valid. Here are some common retirement myths that may be hampering your chances of reaching your retirement goals. “I can work to augment my retirement income.” We've all heard the predictions that the baby…

FridayApr 11, 2008 8:25 am

Angstrom Technologies Corp. (AGMS.OB) to be Included in S&P Market Access Program

Angstrom Technologies announced today that its company information will be available through Standard & Poor's Market Access Program. The S&P program is an information distribution service that allows subscribing, publicly traded companies to have information on their company distributed to users of Standard & Poor's Advisor Insight. Angstrom’s information will be accessible through the program. Such information includes share price, volume, dividends, shares outstanding, company financial position, and earnings. The Standard & Poor's Advisor Insight is used by more than 100,000 investment advisors, providing Angstrom with the opportunity to be reviewed by thousands of investment professionals. Mr. Lalit Jian, CEO…

FridayApr 11, 2008 6:58 am

StockGuru Trade Alert: Guru Profile Financial Media (FNGP) Up More than 52% Since the Beginning of the Week

StockGuru Trade Alert: Guru Profile Financial Media (FNGP) Up More than 52% Since the Beginning of the Week Monday’s Close: $0.17 Today’s High So Far: $0.26

FridayApr 11, 2008 6:56 am

StockGuru Blog: An In-Depth Look at the People Behind NextGen Bioscience (NXGB)

NextGen Bioscience, Inc. is a biotechnology company focused on creating a new generation of targeted human therapeutics which are safe and effective against a broad range of cancers and infectious diseases. Headquartered in London, NextGen’s business model is to acquire promising new patented technologies in the fields of cancer and infectious disease, to add significant value to these by advancing them through toxicological assessment or Phase I clinical trials and then outlicensing the technology to a larger partner who has the necessary infrastructure to take the products to market. Headquartered in London, revenues generated from licensing activities will be reinvested…

FridayApr 11, 2008 6:56 am

StockGuru Trade Alert: Profile Stock NextGen Bioscience (NXGB) Up More than 19% Intraday on Strong, Early Volume

StockGuru Trade Alert: Profile Stock NextGen Bioscience (NXGB) Up More than 19% Intraday on Strong, Early Volume With an Intraday High Today of $0.25, Our Profile NXGB is Up More than 19% and is Up 25% Since Wednesday’s Close! Volume is Strong in the Early Going with More than 96,000 Shares Traded. About NextGen Bioscience: NextGen Bioscience, Inc. (OTC: NXGB) is a drug development biotechnology company focused on the identification, evaluation and acquisition of drug candidates for treatment and prevention of oncological and infectious diseases in human beings. All product candidates target indications with significant unmet need and substantial market…

Site Search

Company Search